Thomas Blevins, MD, an Endocrinologist from Texas Diabetes and Endocrinology in Austin, TX, joins The Huddle to talk about interchangeable biosimilar insulin. We discuss what interchangeability means and the evidence supporting it. You’ll also hear about the options interchangeable biosimilar insulin presents for healthcare systems and people with diabetes.This episode is sponsored by ViatrisResourcesWebinar on Interchangeable Biosimilar Insulin (Free and non-CE):  The New Frontier of Interchangeable Biosimilar Insulins  - bit.ly/3vxUWZ1Tip Sheets on Interchangeable Biosimilar Insulin in English Viatris_Tip_Sheet_v3_04202022 (diabeteseducator.org) and Spanish Viatris_Tip_Sheet_v3_04202022_spa (diabeteseducator.org)Blevins, T. C., Barve, A., Raiter, Y., Aubonnet, P., Athalye, S., Sun, B., & Muniz, R. (2020). Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study. Diabetes, obesity & metabolism, 22(3), 365–372. https://doi.org/10.1111/dom.13904Viatris website: http://www.viatris.com
Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ver todos los episodios